These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20731681)

  • 1. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
    Abbate I; Rozera G; Tommasi C; Bruselles A; Bartolini B; Chillemi G; Nicastri E; Narciso P; Ippolito G; Capobianchi MR
    Clin Microbiol Infect; 2011 May; 17(5):725-31. PubMed ID: 20731681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
    Rozera G; Abbate I; Giombini E; Castagna A; De Luca A; Ceccherini-Silberstein F; Cozzi Lepri A; Cassola G; Torti C; d'Arminio Monforte A; Ippolito G; Capobianchi MR;
    J Antimicrob Chemother; 2014 Nov; 69(11):3085-94. PubMed ID: 25015667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two genotypic algorithms to determine HIV-1 tropism.
    Soulié C; Derache A; Aimé C; Marcelin AG; Carcelain G; Simon A; Katlama C; Calvez V
    HIV Med; 2008 Jan; 9(1):1-5. PubMed ID: 18199166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
    Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.
    Low AJ; Dong W; Chan D; Sing T; Swanstrom R; Jensen M; Pillai S; Good B; Harrigan PR
    AIDS; 2007 Sep; 21(14):F17-24. PubMed ID: 17721088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
    Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
    Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
    Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
    Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
    Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
    J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
    Rodriguez C; Soulié C; Marcelin AG; Calvez V; Descamps D; Charpentier C; Flandre P; Recordon-Pinson P; Bellecave P; Pawlotsky JM; Masquelier B;
    PLoS One; 2015; 10(6):e0127816. PubMed ID: 26068869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
    Gupta S; Neogi U; Srinivasa H; Shet A
    J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
    McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.
    Poveda E; Seclén E; González Mdel M; García F; Chueca N; Aguilera A; Rodríguez JJ; González-Lahoz J; Soriano V
    J Antimicrob Chemother; 2009 May; 63(5):1006-10. PubMed ID: 19261623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
    Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
    Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
    J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.